FAKTOR-OPTIONSSCHEIN - ZEALAND PHARMA | Market Closed - Börse Stuttgart 12:36:13 24/05/2024 am IST | ||
| 9.16 EUR | -2.03% |
|
| Current month | -1.51% | ||
| 1 month | -23.79% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ZEALAND PHARMA A/S
Latest news about ZEALAND PHARMA A/S
More news
| Date | Price | Change |
|---|---|---|
| 23/24/23 | 9.16 | -2.03% |
| 22/24/22 | 9.35 | +3.09% |
| 21/24/21 | 9.07 | -8.84% |
| 20/24/20 | 9.95 | +0.51% |
| 17/24/17 | 9.9 | +8.79% |
Delayed Quote Börse Stuttgart
Last update May 24, 2024 at 12:36 am IST
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | ZEALAND PHARMA A/S |
| Issuer | Morgan Stanley |
| WKN | MG1VGQ |
| ISIN | DE000MG1VGQ4 |
| Date issued | 08/04/2024 |
| Strike | 818 kr |
| Maturity | Unlimited |
| Parity | 2.92 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 13.14 € |
|---|---|
| Lowest since issue | 7.76 € |
| Spread | 0.37 € |
| Spread % | 3.73% |
Company Profile
Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity.
At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.
Sector
-
Consensus: Zealand Pharma A/S
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
603
DKK
Average target price
785.6
DKK
Spread / Average Target
+30.28%
- Stock Market
- Certificates
- Certificat
